Impact of SNPs in ERα corepressor SMRT on breast cancer risk and response to endocrine therapy

被引：0
|
作者：
Hartmaier, R. J.
Skaar, T. C.
Rae, J.
Wang, J.
Li, L.
Oesterreich, S.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Indiana Univ, Indianapolis, IN 46204 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：118S / 119S
页数：2
相关论文
共 50 条
  • [1] Notch signaling in ER plus breast cancer in response to endocrine therapy agents
    Singleton, Ciera S.
    Miele, Lucio
    Crabtree, Judy S.
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
    Sarkar, Swarnavo
    Schechter, Clyde
    Kurian, Allison W.
    Caswell-Jin, Jennifer L.
    Jayasekera, Jinani
    Mandelblatt, Jeanne S.
    NPJ BREAST CANCER, 2025, 11 (01)
  • [3] Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer
    Saladores, Pilar H.
    Precht, Jana C.
    Schroth, Werner
    Brauch, Hiltrud
    Schwab, Matthias
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2013, 13 (04) : 349 - 365
  • [4] Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
    Olukoya, Ayodeji O.
    Stires, Hillary
    Bahnassy, Shaymaa
    Persaud, Sonali
    Guerra, Yanira
    Ranjit, Suman
    Ma, Shihong
    Cruz, M. Idalia
    Benitez, Carlos
    Rozeboom, Aaron M.
    Ceuleers, Hannah
    Berry, Deborah L.
    Jacobsen, Britta M.
    Raj, Ganesh V.
    Riggins, Rebecca B.
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (10)
  • [5] Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse
    Zhang Zhen-huan
    Yamashita, Hiroko
    Toyama, Tatsuya
    Yamamoto, Yutaka
    Kawasoe, Teru
    Ibusuki, Mutsuko
    Tomita, Saori
    Sugiura, Hiroshi
    Kobayashi, Shunzo
    Fujii, Yoshitaka
    Iwase, Hirotaka
    CHINESE MEDICAL JOURNAL, 2009, 122 (15) : 1764 - 1768
  • [6] The impact of neoadjuvant endocrine therapy (NET) in ER plus breast cancer tumor microenvironment and metastasis
    Chondronikola, Anastasia Aristoteleia
    Anastasiadou, Dimitra
    Zintiridou, Aliona
    Duran, Camille L.
    Barth, Nicole
    Karadal-Ferrena, Burcu
    Pereira-Zambalde, Erika
    Ariyan, Lina
    Shukla, Suryansh
    Karagiannis, George S.
    Entenberg, David
    Condeelis, John S.
    Oktay, Maja H.
    CANCER RESEARCH, 2024, 84 (22)
  • [7] Risk of neoadjuvant endocrine therapy in breast cancer
    Ng, C. Ee
    Povey, M.
    Seward, J.
    Redmond, E.
    Harding-Mackean, C.
    BRITISH JOURNAL OF SURGERY, 2018, 105 : 79 - 79
  • [8] PELP-1 promotes adverse endocrine therapy response in ER plus breast cancer
    Rees, Michael
    Smith, Chris
    Barrett-Lee, Peter
    Hiscox, Stephen
    CANCER RESEARCH, 2018, 78 (13)
  • [9] The expression of ERβcx in human breast cancer and the relationship to response to endocrine therapy and survival.
    Palmieri, C
    Lam, E
    Mansi, J
    Madden, P
    Warner, M
    Gustafsson, JA
    Coombes, RC
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S62 - S62
  • [10] Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence
    Carolyn L. Smith
    Ilenia Migliaccio
    Vaishali Chaubal
    Meng-Fen Wu
    Margaret C. Pace
    Ryan Hartmaier
    Shiming Jiang
    Dean P. Edwards
    M. Carolina Gutiérrez
    Susan G. Hilsenbeck
    Steffi Oesterreich
    Breast Cancer Research and Treatment, 2012, 136 : 253 - 265
12345